Compare Stocks: GLSI, SVRA, ANL, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.62 +0.7%	$14.57	$0.88 ▼ $17.25	$998.81M	1.05	185,222 shs	300,393 shs
GLSI Greenwich LifeSciences	$16.53 +9.2%	$16.51	$7.78 ▼ $34.10	$222.23M	1.46	129,925 shs	119,351 shs
KURA Kura Oncology	$10.60 +0.8%	$11.36	$7.36 ▼ $13.90	$935.87M	0.47	1.80 million shs	1.47 million shs
SVRA Savara	$4.92 +1.9%	$5.32	$3.35 ▼ $7.01	$992.37M	0.2	2.35 million shs	1.53 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	+10.39%	-1.59%	0.00%	+57.14%	+781.25%
GLSI Greenwich LifeSciences	-1.62%	-12.74%	-4.78%	-23.54%	+32.34%
KURA Kura Oncology	-1.41%	-1.22%	-15.97%	-8.12%	+4.37%
SVRA Savara	-1.02%	-4.36%	-12.66%	-19.90%	+39.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.62 +0.7%	$14.57	$0.88 ▼ $17.25	$998.81M	1.05	185,222 shs	300,393 shs
GLSI Greenwich LifeSciences	$16.53 +9.2%	$16.51	$7.78 ▼ $34.10	$222.23M	1.46	129,925 shs	119,351 shs
KURA Kura Oncology	$10.60 +0.8%	$11.36	$7.36 ▼ $13.90	$935.87M	0.47	1.80 million shs	1.47 million shs
SVRA Savara	$4.92 +1.9%	$5.32	$3.35 ▼ $7.01	$992.37M	0.2	2.35 million shs	1.53 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	+10.39%	-1.59%	0.00%	+57.14%	+781.25%
GLSI Greenwich LifeSciences	-1.62%	-12.74%	-4.78%	-23.54%	+32.34%
KURA Kura Oncology	-1.41%	-1.22%	-15.97%	-8.12%	+4.37%
SVRA Savara	-1.02%	-4.36%	-12.66%	-19.90%	+39.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.86	Moderate Buy	$29.50	88.86% Upside
GLSI Greenwich LifeSciences	2.00	Hold	$69.00	317.42% Upside
KURA Kura Oncology	2.77	Moderate Buy	$25.69	142.33% Upside
SVRA Savara	2.89	Moderate Buy	$10.25	108.33% Upside

Current Analyst Ratings Breakdown

Latest GLSI, SVRA, ANL, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	SVRA Savara	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
10/7/2026	SVRA Savara	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
10/7/2026	SVRA Savara	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
10/5/2026	KURA Kura Oncology	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
10/1/2026	KURA Kura Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$30.00
9/24/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	201.19	N/A	N/A	($0.21) per share	-74.38
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
KURA Kura Oncology	$67.48M	13.97	N/A	N/A	$2.00 per share	5.30
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	-$19.36M	-$1.54	N/A	N/A	N/A	N/A	-793.81%	-295.32%	11/13/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest GLSI, SVRA, ANL, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	KURA Kura Oncology	-$0.8144	N/A	N/A	N/A	$23.81 million	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	-$0.27	+$0.06	-$0.27	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	N/A
GLSI Greenwich LifeSciences	N/A	1.54	1.54
KURA Kura Oncology	0.12	4.73	4.71
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
GLSI Greenwich LifeSciences	4.16%
KURA Kura Oncology	N/A
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
GLSI Greenwich LifeSciences	51.47%
KURA Kura Oncology	7.60%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
GLSI Greenwich LifeSciences	13	14.68 million	7.12 million	Not Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

GLSI, SVRA, ANL, and KURA Headlines

Recent News About These Companies

JPMorgan starts Savara coverage with USD 12 target for Savara stock

October 8 at 11:21 PM | ad-hoc-news.deA

Savara stock gets USD 12 JPMorgan target before FDA date

October 8 at 3:18 AM | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.

October 8 at 3:13 AM | americanbankingnews.com

Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

October 7 at 12:19 PM | marketbeat.com

JPMorgan Initiates Savara at Overweight With $12 Price Target

October 7 at 12:16 PM | marketscreener.comM

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

October 7 at 12:16 PM | streetinsider.com

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

October 7 at 8:11 AM | marketbeat.com

Savara stock fell 4.66 percent ahead of the November FDA decision

October 4, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Stock Bumped Down to "Sell" by Wall Street Zen

October 4, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

October 4, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Bank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRA

September 30, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen

September 26, 2026 | marketbeat.com

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?

September 24, 2026 | rttnews.com

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Savara (SVRA) Gets a Buy from Piper Sandler

July 24, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GLSI, SVRA, ANL, and KURA Company Descriptions

Adlai Nortye NASDAQ:ANL

$15.62 +0.11 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$16.15 +0.53 (+3.39%)

As of 07:30 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Greenwich LifeSciences NASDAQ:GLSI

$16.53 +1.39 (+9.18%)

Closing price 04:00 PM Eastern

Extended Trading

$16.64 +0.11 (+0.64%)

As of 07:30 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Kura Oncology NASDAQ:KURA

$10.60 +0.08 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$10.61 +0.01 (+0.09%)

As of 07:30 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Savara NASDAQ:SVRA

$4.92 +0.09 (+1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$4.99 +0.07 (+1.40%)

As of 07:30 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLSI, SVRA, ANL, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLSI, SVRA, ANL, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLSI, SVRA, ANL, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GLSI, SVRA, ANL, and KURA Company Descriptions

Adlai Nortye NASDAQ:ANL

Greenwich LifeSciences NASDAQ:GLSI

Kura Oncology NASDAQ:KURA

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLSI, SVRA, ANL, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLSI, SVRA, ANL, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLSI, SVRA, ANL, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GLSI, SVRA, ANL, and KURA Company Descriptions

Adlai Nortye NASDAQ:ANL

Greenwich LifeSciences NASDAQ:GLSI

Kura Oncology NASDAQ:KURA

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools